Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery

National Cancer Institute (NCI)6 个研究点分布在 1 个国家目标入组 50 人开始时间: 2014年10月1日最近更新: 2020年7月7日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方: National Cancer Institute (NCI)
入组人数: 50
试验地点: 6
主要终点: EGFR Phosphorylation in Normal Appearing Bladder Epithelium Adjacent to Tumor

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This randomized phase II trial studies how well erlotinib hydrochloride works in treating patients with bladder cancer undergoing surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

详细描述

PRIMARY OBJECTIVES:

I. To determine if there is a difference in EGFR phosphorylation in normal appearing bladder epithelium adjacent to tumor approximately 9-18 hours post-study dose, between patients randomized to erlotinib hydrochloride (erlotinib) weekly as compared to placebo.

SECONDARY OBJECTIVES:

I. Assess the tolerance of high dose weekly erlotinib compared to placebo. II. Assess the expression of phosphorylated EGF receptor in tumor tissue when available.

III. Assess the expression of e-cadherin and Ki67 in normal and abnormal urothelium.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Participants must have a confirmed or suspected invasive or non-invasive bladder tumor (initial or recurrent) discovered on cystoscopy or radiologic imaging performed within 120 days of randomization
•Patients with muscle invasive bladder cancer (MIBC) must have never received and currently be ineligible for cisplatin-based neoadjuvant chemotherapy due to any of the following:
•Calculated creatinine clearance of < 60 ml/min
•Karnofsky performance status (KPS) < 80
•Solitary kidney or
•Patient refusal to undergo neoadjuvant chemotherapy
•The participant may have prior treatment for bladder tumor (excluding radiation therapy) provided that treatment:
•Was completed greater than 30 days prior to the first dose of study agent
•Participants must be a candidate for a trans-urethral resection of the bladder tumor (TURBT), cystectomy (partial or radical) or cystoscopy with biopsy at a participating organization
•Karnofsky >= 60%
•White blood cells (WBC) >= 3000/mm^3
•Platelets >= 100,000mm^3
•Hemoglobin > 10 g/dL
•Alkaline phosphatase =< 1.5 x upper limit of normal
•Bilirubin =< 1.5 x upper limit of normal
•Aspartate aminotransferase (AST) =< 1.5 x upper limit of normal
•Alanine aminotransferase (ALT) =< 1.5 x upper limit of normal
•Bilirubin for Gilbert's =< 3.0 mg/dl
•A calculated creatinine clearance (Cockcroft Gault) of >= 30 ml/min
•Sodium >= 130 mg/dl and =< upper limit of normal
•Potassium >= 3.0 mg/dl and =< upper limit of normal
•Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
•Ability to understand and the willingness to sign a written informed consent document

排除标准

•Any treatment for the bladder tumor other than intravesical therapy between the pre-study cystoscopy or radiologic imaging which identified the suspected bladder tumor and the scheduled surgical removal or cystoscopy-guided biopsy of that tumor
•Any chemotherapy and/or radiation therapy received =< 3 months of study entry and any immunotherapy received =< 6 months of study entry (with the exception of Bacillus Calmette-Guerin [BCG] treatment)
•Any prior external beam radiation to the pelvis
•A concurrent skin rash or skin condition requiring treatment with a prescription medication
•The following medications may not be taken within 24 hours of the first dose of study agent or at any time while a participant is taking study agent
•Strong CYP3A4 inhibitors including ketoconazole, atazanavir, boceprevir, ceritinib, clarithromycin, cobicistat, darunavir, dasabuvir, idelalisib, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice
•CYP3A4 inducers including rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, primidone, enzalutamide, fosphenytoin, lumacaftor, mitotane, and St. John's wort
•Agents which decrease gastric acid are allowed but should be avoided if possible
•Participants may resume inhibitors or inducers of CYP3A4 > 14 days after their last dose of study agent
•Participants requiring daily use of non-steroidal anti-inflammatory drugs (NSAIDs), with the exception of =< 81 mg aspirin per day; during study participation, acetaminophen is preferred for treatment of pain; the use of NSAIDs, as needed for pain, is discouraged
•Participants may not be receiving any other investigational agents
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or clindamycin (topical agent for potential skin toxicity)
•An underlying predisposition to rectal or gastrointestinal bleeding or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
•Females who are pregnant or lactating may not participate in this study; females of child-bearing potential must have a negative pregnancy test before starting study agent; patients who have had a bilateral oophorectomy, hysterectomy, or are greater than 1 year since their last menses are not considered to be of child-bearing potential